Posted by Michael Wonder on 21 May 2025
Lilly's Kisunla (donanemab) receives marketing authorisation in Australia for the treatment of early symptomatic Alzheimer's disease
21 May 2025 - The authorisation in Australia is for adult patients who are Apolipoprotein E-ε4 heterozygotes or non-carriers.
Eli Lilly announced today that the TGA has granted marketing authorisation for Kisunla (donanemab), an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in adults who are apolipoprotein E ε4 heterozygotes or non-carriers.
